Announcement • Jun 04
IMPACT Therapeutics, Inc, Annual General Meeting, Jun 25, 2026 IMPACT Therapeutics, Inc, Annual General Meeting, Jun 25, 2026, at 10:00 China Standard Time. Location: board room, 27f, new bund times square, 399 west haiyang rd., pudong district, shanghai China Announcement • Jun 02
Impact Therapeutics, Inc Presents Phase 1/2 Clinical Data for Imp1734 At 2026 Asco Annual Meeting IMPACT Therapeutics Inc. made an announcement on a voluntary basis to inform the shareholders and potential investors of the latest business updates. The latest Phase 1/2 clinical data for its highly selective PARP1 inhibitor, IMP1734 (also known as EIK1003), were presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held from May 29 to June 2, 2026, in Chicago, USA. The poster (Abstract #3102) featured data on the safety and preliminary efficacy of IMP1734 both as monotherapy and in combination with paclitaxel for the treatment of advanced solid tumors. Detailed information on this study selected for ASCO 2026 is as follows: Title: EIK1003 (IMP1734), A PARP1-Selective Inhibitor, in Combination with Paclitaxel: Initial Combination and Updated Monotherapy Results from a Phase 1/2 Study EIK1003-001 in Advanced Solid Tumors. Updated Results from IMP1734 Monotherapy (Cohort 1A): Among 49 efficacy-evaluable patients with advanced solid tumors, the objective response rate (ORR) was 14.3%; all 7 responses were partial responses (PR). The disease control rate (DCR) was 38.8%. For confirmed responders, the median duration of response (DOR) was 7.8 months (range: 6.0-15.9+ months). In PARP inhibitor-naïve patients, the ORR was 26.7%. The safety profile was consistent with prior data and was generally favorable. Results from IMP1734 in Combination with weekly Paclitaxel (Cohort 1C): Among 53 efficacy-evaluable patients, the ORR was 24.5%, including 1 confirmed complete response (CR) and 12 partial responses (PR). Of these responders, 92% had prior taxane exposure, indicated that the antitumor activity was observed despite prior taxane exposure. By tumor type, the ORR was 29.6% in patients with epithelial ovarian cancer and 19.2% in patients with HER2- breast cancer. IMP1734 + weekly paclitaxel showed a manageable safety profile in an advanced-line population, with Grade =3 TEAEs occurring in 75.0% of patients. The most common Grade =3 TEAEs were neutropenia (50.0%) and anemia (13.3%). All 8 participants who developed Grade =3 anemia had Grade 1-2 anemia at baseline. No unexpected safety signals were observed, and the hematologic toxicity profile was manageable in this heavily pre-treated population and in line with the effects of the weekly paclitaxel. IMP1734 monotherapy demonstrated durable antitumor activity and a favorable safety profile in a heavily pre-treated patient population with HRR-mutated advanced solid tumors. The clinical data for IMP1734 in combination with weekly paclitaxel provided the first clinical evidence that a PARP1-selective inhibitor can be safely combined with cytotoxic chemotherapy, thereby enabling a combination approach that was previously not feasible with non-selective PARP inhibitors. IMP1734 is a novel PARP1-selective inhibitor with high potency of inhibiting PARP1 and low activity of inhibiting PARP2. Preclinical in vivo models demonstrated high anti-tumor activities and a wide therapeutic window. The improved therapeutic index of IMP1734 over currently marketed non-selective PARP1/2 inhibitors supports its development as monotherapy and in combination with other agents. Overall, phase I studies demonstrated relatively low rates of hematologic toxicity, and clinical activity was observed at most doses tested, as evidenced by target lesion size reduction and durable responses. In addition, tolerability and efficacy are being evaluated in combination with Abiraterone and Paclitaxel, respectively, and results of these combination studies will be disclosed at future medical meetings. In May 2023, the Company and Eikon Therapeutics Inc. entered into an exclusive global licensing and collaboration agreement. Under the agreement, EIKON holds the exclusive rights to co-develop, register, manufacture, and commercialize IMP1734 and other PARP1-selective inhibitors in all territories outside of Greater China. Announcement • May 13
IMPACT Therapeutics, Inc has completed an IPO in the amount of HKD 843.7377 million. IMPACT Therapeutics, Inc has completed an IPO in the amount of HKD 843.7377 million.
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 4,197,800
Price\Range: HKD 20.1
Discount Per Security: HKD 0.804
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 23,849,200
Price\Range: HKD 20.1
Discount Per Security: HKD 0.804
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 13,930,000
Price\Range: HKD 20.1
Discount Per Security: HKD 0.804
Transaction Features: Regulation S; Rule 144A; Sponsor Backed Offering 
